Results 1,541-1,560 of 12,424 for speaker:Louise O'Reilly
- Select Committee on Health: Health and Social Care Professionals (Amendment) Bill 2017: Committee Stage (11 Jul 2017)
Louise O'Reilly: Yes, on the basis of the discussion we just had while reserving the right to table it again on Report Stage.
- Select Committee on Health: Health and Social Care Professionals (Amendment) Bill 2017: Committee Stage (11 Jul 2017)
Louise O'Reilly: I think the Deputy means amendment No. 7.
- Select Committee on Health: Health and Social Care Professionals (Amendment) Bill 2017: Committee Stage (11 Jul 2017)
Louise O'Reilly: Based on the discussion, I am happy to withdraw the amendment but as someone who has represented people in fitness to practice forums, it is imperative the people who are practicing under these regulations and under this legislation are given as much clarity as possible. They and members of the public need to understand, as we do, that this is a public safety issue. To be fair to the people...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: The purpose of this session is to engage with the HSE and the National Centre for Pharmacoeconomics, NCPE, on the processes and criteria used when evaluating orphan drugs. On behalf of the committee I welcome Mr. John Hennessy, Mr. Shaun Flanagan and Mr. Ray Mitchell of the HSE; Professor Michael Barry and Dr. Lesley Tilson of the NCPE. By virtue of section 17(2)(l) of the Defamation Act...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I thank Mr. Hennessy and invite Professor Barry to make his opening remarks.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Thank you. Six members of the committee have already indicated they wish to put questions. We will take them in batches of three. That is not an ideal system so I ask the witnesses to take a note so they can reply to everybody. This is a detailed subject and we can take our time and get the answers. However, when the questioners are in batches sometimes the first questioner does not get...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: A broad range of questions have been asked. I ask witnesses to do their best to answer. The asking of questions in batches is not ideal but it is the procedure of the committee. I ask witnesses to try to answer all questions posed.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Could Mr. Hennessy explain the difference between the two different assessments and how IPHA's figure is different from the HSE's?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Senator Burke wants to come back in at this point.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: The Senator has made that point. Can we resume going back through the questions and then the Senator will have an opportunity-----
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Okay, that is fair.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Very briefly, Senator Mullen. Other people are also trying to get in.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I am going to ask Senator Mullen to hold his questions for now because other members have indicated and I know they are under time pressure.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I did not say that.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: A point was raised about reimbursement and figures that I got in response to a parliamentary question indicate that there are nine drugs that have cleared the hurdle and await approval of some form from the Health Service Executive, HSE. That ties in with many of the questions being asked this morning. People who watch this process closely do not do it for fun. They do it because they have...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I ask Mr. Hennessy to be very specific and not vague. When he says that we will require additional resourcing, is he saying that, as we sit here, the money is not available to fund these, so those people who are waiting for those nine drugs may as well forget waiting, because there is no point and that is not going to happen? Is it going to happen? Saying that there is a funding issue is...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Presumably they have passed the clinical effectiveness tests at this point.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: The clinical effectiveness test is not an issue. The issue then is the €120 million over five years.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: And that is all that it is?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Does Mr. Hennessy have any indication of whether it in the HSE's plans, budgets or is any movement going to be made in this regard, or will those nine drugs simply sit waiting? When Mr. Hennessy talks about effectiveness, outcomes and such, all of those hurdles have been cleared and now we find ourselves with nine drugs sitting somewhere in some sort of funding-related limbo which they may...